PF-07941944 / Pfizer - LARVOL DELTA

A PHASE-1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF AN RSV N-PROTEIN INHIBITOR PF-07941944 IN HEALTHY PARTICIPANTS FOR THE TREATMENT OF RSV (RSVVW 2026) - "All tested doses achieved exposures above EC90. Given the safety and PK profile observed after single and multiple doses, PF-07941944 allows for flexibility in the dosing regimen for patients with RSV disease, which can be optimized in future clinical trials."

Clinical • First-in-human • P1 data • PK/PD data • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • CYP3A4

A Study to Learn How Different Amounts of the Study Medicine Called PF-07941944 Are Tolerated in the Body of Healthy Adults. (clinicaltrials.gov) - P1 | N=25 | Completed | Sponsor: Pfizer | Recruiting ➔ Completed | N=66 ➔ 25

Enrollment change • Trial completion

A Study to Learn How Different Amounts of the Study Medicine Called PF-07941944 Are Tolerated in the Body of Healthy Adults. (clinicaltrials.gov) - P1 | N=66 | Recruiting | Sponsor: Pfizer

New P1 trial